Full-Time

Senior Director

Pre-Clinical Science

Posted on 8/9/2025

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharma developing eye-care therapies

Compensation Overview

$217.5k - $304.5k/yr

+ Bonus + Stock Equity

Irvine, CA, USA

Remote

Hybrid work environment; remote work is an option.

Category
Lab & Research (1)
Required Skills
Data Analysis
Requirements
  • PhD degree in pharmacology, toxicology or related field with 15+ years’ experience in the pharmaceutical or industry setting.
  • Experience in ophthalmology product development and understanding ocular safety risk is highly desired.
  • Outstanding organizational and interpersonal skills, and outstanding ability to manage relationships and influence others.
  • Proven experience in designing non-GLP and GLP safety studies.
  • Demonstrated ability to work closely with CROs and provide close oversight of vendors, budget planning and coordination.
  • Hands on experience in relevant laboratory techniques.
  • Willingness to be both a strategic leader and hands-on problem solver.
  • Experience allocating resources and managing budgets.
  • Proven knowledge of FDA regulations.
  • Superior oral and written communication skills are required, and the ability to work effectively with senior management. Strong analytical and scientific writing skills.
  • Strong creativity, independent thinking and results orientation is required.
  • Must have high ethical standards and impeccable integrity.
  • Strong people leadership abilities, including inspiring and motivating a high performing team, setting clear direction, enabling cross-functional collaboration, empowering people, and developing and coaching talent.
  • Ability to understand stakeholder concerns and frame issues/proposals to influence decision making.
  • Superior knowledge and understanding of emerging research, mechanisms of action and disease models in anterior and posterior segment eye care diseases, preclinically and clinically is desired.
  • Knowledge of the clinical landscape in ophthalmology indications with good understanding of novel agents and impact to this landscape.
  • Superior interpersonal skills, diplomacy, and positive-influencing abilities.
  • Leadership ability to drive decision-making within a multi-disciplinary, matrix teams.
  • Scientifically independent.
  • Enterprise and entrepreneurial mindset.
Responsibilities
  • Collaborate with key experts across the company including Clinical Development, Regulatory Affairs, CMC and Innovation lab to appropriately advise on non-clinical strategy for early POC trials as well as to appropriately meet global regulatory requirements.
  • Establish key relationships with consultants and CROs to conduct the studies.
  • Build non-clinical functional capabilities with a hybrid model of internal and external resources that is scalable.
  • Collaborate with Innovation Lab and BD (on due diligences) to develop integrated Safety Assessment, Toxicology and PK program strategies.
  • Lead the conduct, interpretation and reporting of Toxicology, PK and other relevant non—clinical studies/data.
  • Critically evaluate toxicology results and provide strategic guidance to project teams and senior management on the potential impact of toxicology results on Program and Clinical/Regulatory strategy.
  • Develop experimental strategy to understand the mechanisms of toxicity as needed.
  • Responsible for the preparation of Safety Pharmacology and Toxicology sections of regulatory documents (IND, CTA, NDA, BLA, briefing books, Investigator brochures, etc.).
  • Interface with regulatory agencies as required.
  • Responsible for the preparation of data summaries and presentations of results to internal and external stakeholders, as required.
  • Responsible for building and maintaining effective CRO and consultant relationships that support the execution of non-GLP and GLP toxicology/biodistribution studies.
  • Review study protocols and draft study reports, providing feedback as needed and responsible for report finalization.
  • Develop and implement SOPs to guide functional activities. Oversee the development of the nonclinical regulatory strategy, design of experiments, interpretation of data and oral and written presentation of results.
  • Oversee the review and approval of all preclinical protocols and final reports for nonclinical development studies and ensure data quality and integrity for preclinical sites.
  • Effectively communicate preclinical findings to project teams, senior management, regulators and other external partners.
  • Provide technical support to various departments within the company with respect to safety assessment, PK and toxicology.
  • Bring scientific expertise to due diligence in collaboration with BD team, identify main risks and mitigation plan in their area of expertise.
  • Build open relationships with peers and external partners to ensure best decision making.
  • Clearly identify risks and mitigation plans. Ensures team contribution to clinical and regulatory development plan.
Desired Qualifications
  • Track record of success and measurable contribution in moving ophthalmology therapeutic programs forward through preclinical and/or clinical development in an academic or industry setting.
  • Experience in research and/or development of anterior and/or posterior eye care segment therapies.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for eye care and infectious diseases. Its FDA-approved product, XDEMVY (lotilaner ophthalmic solution 0.25%), treats Demodex Blepharitis by killing Demodex mites on the eyelids. The company also has a pipeline targeting conditions like Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea, and it earns revenue from selling approved products and collaborating with partners. Its goal is to address unmet medical needs by developing, commercializing, and expanding collaborations to reach more patients.

Company Size

201-500

Company Stage

IPO

Headquarters

Irvine, California

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • XDEMVY nets $145 million Q1 2026 sales, up 85% year-over-year.
  • 2026 guidance projects $670-$700 million XDEMVY sales, 50% growth.
  • $200 million Pharmakon financing supports sales force expansion without dilution.

What critics are saying

  • ICRx Cliradex wipes erode XDEMVY sales by 15-20% within 6-12 months.
  • TP-05 CALLIOPE trial fails efficacy, halts Phase 3 in 12-18 months.
  • Aldeyra reproxalap captures 25% Demodex market share post-2027 approval.

What makes Tarsus Pharamceuticals unique

  • XDEMVY is the only FDA-approved treatment for Demodex blepharitis.
  • TP-05 advances as first-in-class oral Lyme disease preventive in Phase 2 CALLIOPE trial.
  • TP-04 targets untreated ocular rosacea market in Phase 2 with H1 2027 data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Apr 3rd, 2026
Tarsus Pharmaceuticals doses first patient in Phase 2 Lyme disease prevention trial with TP-05

Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial of TP-05, an investigational oral therapy aimed at preventing Lyme disease in approximately 700 at-risk adults across endemic US regions. The programme targets a significant unmet need as a potential first-in-class, non-vaccine prophylactic for Lyme disease, where no FDA-approved preventive drugs currently exist. Whilst the trial marks progress, near-term investment focus remains on XDEMVY adoption and margins. The company recently received a $15 million milestone payment tied to TP-03 approval in China, highlighting monetisation of its lotilaner platform beyond the US. Analyst projections for Tarsus vary widely, with some forecasting $847 million revenue and $237 million earnings by 2028, whilst more cautious estimates suggest $988 million revenue and $188 million earnings by 2029.

Yahoo Finance
Mar 24th, 2026
Tarsus Pharma CHRO sells $839K in shares via mandatory RSU vesting amid 20% stock surge

Dianne Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals, sold 12,274 shares of common stock worth approximately $839,000 between 17 and 19 March 2026. The sale represented 25.95% of her direct holdings, reducing her position from 47,302 to 35,028 shares. The transaction was a mandatory "sell to cover" arrangement tied to RSU vesting for tax withholding purposes, rather than a discretionary sale. Shares sold at a weighted average price of $68.36. Tarsus Pharmaceuticals generated $451.4 million in net product sales in 2025, more than doubling from the prior year, driven by adoption of its lead product XDEMVY. The company narrowed its net loss to $66.4 million and ended 2025 with over $417 million in cash and marketable securities.

Yahoo Finance
Feb 24th, 2026
Tarsus Pharmaceuticals projects $670M–$700M 2026 sales as XDEMVY hits profitability

Tarsus Pharmaceuticals reported $450 million in full-year net sales for 2025, with its XDEMVY treatment achieving product-line profitability. The company has expanded its addressable market from nine million to 25 million Americans with Demodex blepharitis as screening becomes routine amongst eye care professionals. The firm projected 2026 net product sales between $670 million and $700 million, representing approximately 50% annual growth at the midpoint. Direct-to-consumer awareness reached 25% amongst surveyed patients, significantly increasing treatment requests. Tarsus plans to expand its sales force by 15 to 20 key account leaders and will initiate a Phase II trial for TP-05 in Lyme disease prevention in Q2 2026. The company has also launched the first Phase II trial for TP-04 in Ocular Rosacea, a category with no currently approved FDA treatments.

GlobeNewswire
Mar 13th, 2025
Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of...

MarketBeat
Nov 22nd, 2024
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).

INACTIVE